Should Gilead Sciences, Inc. Pay a Dividend?
Shares of Gilead Sciences have skyrocketed over the past two years, propelling the company into the upper echelons of the healthcare sector in terms of market cap. With all of its new peer group offering a dividend, should Gilead follow suit?
Will Insulin Pricing Be MannKind Corporation's Downfall?
MannKind marketing partner Sanofi had to discount its Lantus insulin to get insurers to cover the drug.
Should MannKind's Shareholders Buy Al Mann's New Company?
Three Motley Fool analysts give their thoughts on whether or not to buy Al Mann's Second Sight on its initial public offering.
Gilead Sciences Inc. Just Paid $125 Million for Something It Can't Use for a Year
Gilead's newly acquired priority review voucher is useful, but requires the biotech to give the FDA a 365-day warning that it's going to use the voucher.
Stop Worrying About Ebola: This is a Much More Pressing Concern
Ebola may be garnering all of the headlines, but this infectious disease has been a contributing factor to the eighth leading cause of death in the U.S.